NeuroRx: NeuroRx is developing the first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Phase 2b/3 development, initiated in July 2019 (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. NRX-101 is a patented, oral, fixed-dose combination of two FDA approved drugs: D-cycloserine, an N- methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, an FDA-approved D2/5-HT2a receptor antagonist. The Company reported Phase 2 efficacy and safety data for NRX-011 in December 2018, suggesting potential for NRX-101 in maintaining remission from several bipolar depression with acute suicidal ideation following an initial stabilization with ketamine. There is no currently approved drug for bipolar depression with suicidal ideation and the only FDA-approved treatment remains ECT.
Clinical Stage
Phase III
Disease Space
Central Nervous System
Market Cap
913 North Market Street
Suite 200
Wilmington, DE 19801
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout KOL Day

New York City, November 15, 2019

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020